Protalix Biotherapeutics Inc
Biotechnology
Protalix Biotherapeutics Inc (PLX) Stock News
The latest PLX headlines and market coverage — 4 recent stories, updated throughout the day.
- Zacks Investment Research·Neutral
MPLX LP (MPLX) Outperforms Broader Market: What You Need to Know
MPLX LP closed at $57.37, up 1.76% for the day, outperforming the S&P 500. However, the stock has declined 5.51% over the past month. The company is expected to report Q3 2026 earnings on November 3 with an EPS of $1.13 (down 25.66% YoY) and revenue of $3.3 billion (down 8.71% YoY). MPLX holds a Zacks Rank #3 (Hold) with a Forward P/E of 13.25, trading at a discount to its industry average.
- Zacks Investment Research·
MPLX LP (MPLX) Suffers a Larger Drop Than the General Market: Key Insights
MPLX LP closed at $56.32, down 1.28% and underperforming the S&P 500's 0.25% loss. The stock has fallen 3.45% over the past month. Upcoming earnings on November 3, 2026 are expected to show a 25.66% year-over-year EPS decline to $1.13 per share, with revenue projected at $3.3 billion (down 8.71%). The company holds a Zacks Rank of #3 (Hold) with a Forward P/E of 13.41, trading at a discount to its industry average.
- The Motley Fool·
Why MPLX Stock Is Suddenly Trending on Wall Street
MPLX, a midstream operator with dominant positioning in natural gas gathering and processing in the Permian Basin, is trending on Wall Street due to strong Q2 earnings, a 7.2% dividend yield, and analyst upgrades. The company increased 2026 spending plans to $2.9 billion to capitalize on growing demand for natural gas and NGL infrastructure, with expected 12.5% dividend growth through 2027. U.S. natural gas demand is projected to increase 15% through 2030, supported by LNG and data center needs.
- The Motley Fool·
Protalix (PLX) Q2 2026 Earnings Call Transcript
Protalix reported Q2 2026 revenues of $19.9 million, up from $15.7 million year-over-year, driven by Elfabrio sales through its Chiesi partnership. The company posted net income of $3.8 million ($0.05 per share) and H1 net income of $22.1 million. Full-year 2026 revenue guidance remains $78-83 million. The company maintains a strong cash position of $40.7 million with zero debt and expects PRX-115 Phase 2 RELEASE study top-line results in H2 2027.